Company Overview
Orchestra BioMed Holdings, Inc. operates as a biomedical company within the United States, focusing on the development of bioelectronic therapy candidates such as Atrioventricular Interval Modulation designed to immediately and substantially lower blood pressure. The company functions within the healthcare sector, specifically under the biotechnology industry, which implies a focus on innovative drug development and medical device research rather than traditional pharmaceutical manufacturing. Orchestra BioMed Holdings, Inc. maintains a market capitalization of $267.44M and reports an annual revenue of $33.48M based on trailing twelve-month figures. With an employee count of 86, the company demonstrates a lean organizational structure typical of early-to-mid-stage biotechnology firms where human capital is concentrated in specialized research and development roles. These financial metrics indicate that the company holds a mid-cap position in its sector, suggesting it has moved beyond the initial seed stage but has not yet reached the revenue scale of large-cap biotechnology enterprises, reflecting a specific phase in its lifecycle where capital efficiency is paramount.
Financial Health
The company generated revenue of $33.48M over the trailing twelve months, yet reported a net income of -$52,955,000 and an EBITDA of -$51,480,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development expenditures, clinical trial costs, and general administrative overhead common in biotechnology. The company reported a free cash flow of -$20,247,876, which indicates a continuous consumption of cash resources and a reliance on external financing to fund ongoing operations and product development initiatives. In terms of profitability margins, the gross margin stands at 99.4%, indicating that the cost of goods sold is negligible relative to revenue, while the operating margin is 21.8% and the profit margin is -157.4%. The negative profit margin confirms that total operating expenses, including R&D and SG&A, significantly exceed the gross profit generated. On the balance sheet, Orchestra BioMed Holdings, Inc. holds cash of $106.51M against total debt of $15.96M, resulting in a debt-to-equity ratio of 25.17. Despite the positive debt-to-equity figure, the magnitude of cash relative to debt suggests a conservative liquidity position where the company possesses ample resources to service obligations without immediate refinancing needs. The current ratio is 6.45, which indicates a very strong short-term liquidity position where current assets are more than six times greater than current liabilities. Return on equity is -109.4% and return on assets is -33.9%, metrics that reveal management is currently deploying capital to generate losses, a typical characteristic of growth-stage biotechs investing heavily in pipeline advancement rather than immediate shareholder returns.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is -2.75. The difference between these metrics, specifically the negative forward P/E, implies that the market is pricing in future earnings that are not yet realized or are expected to remain negative in the near term. The price-to-book ratio is 4.87, which indicates that the stock is trading at a significant premium over its book value, reflecting market optimism regarding the potential value of the company's intangible assets and pipeline. The price-to-sales ratio is 7.99, and the EV/EBITDA is -3.63, suggesting that valuation is being driven primarily by revenue multiple expansion rather than earnings power, as the negative EV/EBITDA highlights the lack of current cash flow generation. The 52-week high is $5.42 and the 52-week low is $2.20. Without a specific current price provided in the facts, the trading range defines the volatility band within which the stock has operated over the past year. The beta value is 0.59, which indicates that the stock price volatility is lower than that of the broader market, suggesting the asset may be less sensitive to general market fluctuations compared to high-beta equities.
Growth & Income
Orchestra BioMed Holdings, Inc. reported a revenue growth of 12120.2% year over year, while earnings growth is N/A due to the absence of positive prior-year earnings. The disparity between the massive revenue growth figure and the lack of earnings growth implies that the top-line expansion is not yet translating into profitability, likely due to the heavy upfront costs associated with bringing new therapies to market. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that it reinvests all available earnings and cash reserves into research, development, and operational growth rather than distributing income to shareholders. The overall growth and income profile is defined by aggressive top-line expansion funded by a strong cash balance, with no current income distribution mechanism, focusing entirely on capital appreciation potential through future product commercialization.